NOACS for stroke prevention in non-valvular AF: has clinical practice changed?

Dr Peter Blombery outlines the new era in stroke prevention for atrial fibrillation patients.

In atrial fibrillation (AF), warfarin reduces the incidence of stroke and systemic embolism by 64% vs placebo1 but its use is associated with significant challenges2,3 and a significant risk of intracranial haemorrhage (ICH).1,2